Table 1.

Clinical studies about PARPi/ICIs.

ClinicalTrials.gov identifier	Combination	Phase	Cancer type	References
NCT02657889	Niraparib + pembrolizumab	I/II	Basket study in TNBC and ovarian cancer	Konstantinopoulos et al,89 Vinayak et al90
NCT02849496	Veliparib + atezolizumab	II	HR-deficient and HER-2–negative TNBC	N/A
NCT03101280	Rucaparib + atezolizumab	I	BRCA+ ovarian cancer and TNBC	N/A
NCT03598270	Niraparib + atezolizumab	III	Maintenance treatment of recurrent ovarian cancer	N/A
NCT03522246	Rucaparib + nivolumab	III	Front-line ovarian cancer	N/A
NCT03642132	Talazoparib + avelumab	III	Front-line ovarian cancer	N/A
NCT03602859	Niraparib + TSR-042	III	Front-line ovarian cancer	N/A
NCT03307785	Niraparib + TSR-042	I/II	Solid tumors	N/A
NCT03565991	Talazoparib + avelumab	II	BRCA/ATM-mutant solid tumors	N/A
NCT03330405	Talazoparib + avelumab	II	Basket study in ovarian cancer, HER2- breast cancer, mCRPC, bladder cancer, and NSCLC	N/A
NCT02660034	Pamiparib + tislelizumab	I	Basket study in TNBC, ovarian cancer, mCRPC, SCLC, bladder cancer, HER2-gastric cancer, pancreatic cancer, and other solid tumors	Friedlander et al91
NCT02734004	Olaparib + durvalumab	II	Basket study in germline BRCA-mutant ovarian, HER2-breast cancer, gastric cancer, and relapsed SCLC	Krebs et al92
NCT02484404	Olaparib + durvalumab	II	Basket study in ovarian cancer, TNBC, NSCLC, SCLC, mCRPC, and microsatellite stable colorectal cancer	Thomas et al,56 Karzai et al93
NCT03572478	Rucaparib + nivolumab	I/IIa	Prostate/endometrial cancers	N/A
NCT03338790	Rucaparib + nivolumab	II	Umbrella study in mCRPC	N/A
NCT02861573	Olaparib + pembrolizumab	I	Umbrella study in mCRPC	N/A
NCT02546661	Olaparib + durvalumab	Ib	Umbrella study in HR-deficient muscle invasive bladder cancer	N/A
NCT03459846	Olaparib + durvalumab	II	Cisplatin-ineligible bladder cancer	N/A
NCT03534492	Olaparib + durvalumab	II	Study before surgery of resectable urothelial bladder cancer	N/A
NCT03334617	Olaparib + durvalumab	II	Umbrella study in patients with NSCLC who have progressed on anti–PD-1/PD-L1	N/A
NCT03308942	Niraparib + PD-1 inhibitor	II	NSCLC	N/A

Abbreviations: ATM, ataxia telangiectasia mutated gene; BRCA, breast cancer susceptibility gene; HER-2, human epidermal growth factor receptor-2; HR, homologous recombination; ICI, immune checkpoint inhibitor; mCRPC, metastatic castration-resistant prostate cancer; NSCLC, non–small cell lung cancer; PARPi, poly (ADP-ribose) polymerase inhibitors; PD-1, programmed cell death 1; SCLC, small cell lung cancer; TNBC, triple-negative breast cancer.